Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)

Jacob Appelbaum, Suravi Raychaudhuri, Katie Russell, Kimberly Cadiz, Stacey Fuller, Anna Halpern, Cristina Maria Ghiuzeli, Raya Mawad, Vivian Oehler, Ryan Cassaday, Jason Cooper, Paul Hendrie, Megan Othus, Mary-Elizabeth Percival, Roland Walter

Blood (2025) 146 (Supplement 1): 3422.

https://doi.org/10.1182/blood-2025-3422

Published: 2025

Journal Articles

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Shahanawaz Jiwani, Min Fang, Cecilia Yeung, Xiaoyu QU, Xueyan Chen, Brent Wood, Andrea Zak, Srikrishna Narava, Ting-Chia Chang, Celso Baldivieso, Megha Kamath, Megan Othus, Bhanumati Ramineni, Harry Erba, Mark Litzow, James Doroshow, Lyndsay Harris, Jerald Radich, Richard Little

Blood (2025) 146 (Supplement 1): 340.

https://doi.org/10.1182/blood-2025-340

Published: 2025

Journal Articles

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

Min Fang, Megan Othus, Xiaoyu QU, Kate Kroeger, Jacob Wilson, Alyssa Ng, Cecilia Yeung, Shahanawaz Jiwani, Lyndsay Harris, Brent Wood, Harry Erba, Jerald Radich, Richard Little

Blood (2025) 146 (Supplement 1): 3501.

https://doi.org/10.1182/blood-2025-3501

Published: 2025

Journal Articles

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML.

Brenda Castillo, Jacob Appelbaum, Megan Othus, Katie Russell, Rutu Vyas, Paul Hendrie, Anna Halpern, Cristina Maria Ghiuzeli, Ryan Cassaday, Raya Mawad, Mary-Elizabeth Percival, Roland Walter

Blood (2025) 146 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2025-3378

Published: 2025

Journal Articles

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Cecilia Yeung, Olga Sala Torra, Brent Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron Gerds, Susan O'Brien, Jane Liesveld, Megan Othus, Mark Litzow, Richard Stone, Jerald Radich, Harry Erba

Blood (2025) 146 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2025-3343

Published: 2025

Journal Articles

Impact of MDS-associated mutations and age on outcomes in NPM1-mutated AML

Vivian Liu, Megan Othus, Rhonda Ries, Jasmine Naru, Era Pogosova-Agadjanyan, Frederick Appelbaum, Lan Beppu, Thomas Chauncey, Harry Erba, John Godwin, Matthew Fitzgibbon, Min Fang, Stanley Lee, Anna Moseley, Jerald Radich, Cheryl Willman, Feinan Wu, Soheil Meshinchi, Derek Stirewalt

Blood (2025) 146 (Supplement 1): 6999.

https://doi.org/10.1182/blood-2025-6999

Published: 2025

Journal Articles

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

Sarah Peterson, Megan Othus, Katie Russell, Carole Shaw, Rutu Vyas, Anna Halpern, Cristina Maria Ghiuzeli, Paul Hendrie, Ryan Cassaday, Raya Mawad, Roland Walter, Jacob Appelbaum, Mary-Elizabeth Percival

Blood (2025) 146 (Supplement 1): 5265.

https://doi.org/10.1182/blood-2025-5265

Published: 2025

Journal Articles

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Eric Huselton, Uma Borate, John Reagan, Richard Little, Steven Gore, Megan Othus, Anna Moseley, Manu Pandey, Xin Wang, Laura Michaelis, Geoffrey Uy, Anjali Advani, Harry Erba

Blood (2025) 146 (Supplement 1): 3466.

https://doi.org/10.1182/blood-2025-3466

Published: 2025

Journal Articles

Association of CD34+ cell dose on outcome after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (PBSCT) for adults with Acute Myeloid Leukemia (AML) in measurable residual disease (MRD)-negative remission

Margery Gang, Megan Othus, Anne-Chloe Olix, Fazal Yakub, Gurbani Kaur, Chris Davis, Ryan Basom, Kate Markey, Derek Stirewalt, Laura Connelly-Smith, Filippo Milano, Roland Walter

Blood (2025) 146 (Supplement 1): 2481.

https://doi.org/10.1182/blood-2025-2481

Published: 2025

Journal Articles

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Jason Gilbert, Megan Othus, Suravi Raychaudhuri, Katie Russell, Carole Shaw, Rutu Vyas, Anna Halpern, Paul Hendrie, Raya Mawad, Cristina Maria Ghiuzeli, Ryan Cassaday, Roland Walter, Jacob Appelbaum, Mary-Elizabeth Percival

Blood (2025) 146 (Supplement 1): 7022.

https://doi.org/10.1182/blood-2025-7022

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report

Min Fang, Megan Othus, Kate Kroeger, Thaiha Nguyen, Xiaoyu QU, Brent Wood, Lyndsay Harris, Harry Erba, Jerald Radich, Richard Little, Cecilia Yeung, Shahanawaz Jiwani

Blood (2025) 146 (Supplement 1): 5276.

https://doi.org/10.1182/blood-2025-5276

Published: 2025

Journal Articles

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

Blood (2025) 146 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2025-1677

Published: 2025

Journal Articles

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

Anna Halpern, Megan Othus, Mary-Elizabeth Percival, Cristina Maria Ghiuzeli, Jacob Appelbaum, Paul Hendrie, Ryan Cassaday, Bart Scott, Jason Cooper, Sioban Keel, Vivian Oehler, Johnnie Orozco, Katie Russell, Raya Mawad, Roland Walter

Blood (2025) 146 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2025-1663

Published: 2025

Journal Articles

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Vivian M. Liu, Megan Othus, Rhonda E. Ries, Jasmine Naru, Era L. Pogosova-Agadjanyan, Frederick R. Appelbaum, Lan W. Beppu, Thomas R. Chauncey, Harry P. Erba, John E. Godwin, Matthew Fitzgibbon, Min Fang, Stanley C. Lee, Anna B. Moseley, Jerald P. Radich, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt

Blood (2024) 144 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2024-198506

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Phuong T Vo, Brenda M. Sandmaier, Megan Othus, Naveed Ali, Eduardo Rodríguez-Arbolí, Corentin Orvain, Chris Davis, Ryan S. Basom, Rainer F. Storb, Roland B. Walter

Blood (2024) 144 (Supplement 1): 7314.

https://doi.org/10.1182/blood-2024-206221

Published: 2024

Journal Articles

4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)

Suravi Raychaudhuri, Ted Gooley, Megan Othus, Xiaoyu Qu, Carole Shaw, Kathryn Russell, Rutu D. Vyas, Jacob S. Appelbaum, Anna B. Halpern, Roland B. Walter, Harry P. Erba, Min Fang, Mary-Elizabeth M. Percival

Blood (2024) 144 (Supplement 1): 1530.

https://doi.org/10.1182/blood-2024-201213

Published: 2024

Journal Articles

Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Daniel J. Olivieri, Alexis Berridge-Green, Megan Othus, Anna B. Moseley, Jerald P. Radich, Anjali S. Advani, Harry P. Erba, Roland B. Walter

Blood (2024) 144 (Supplement 1): 2414.

https://doi.org/10.1182/blood-2024-199817

Published: 2024

Journal Articles

Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Anjali S. Advani, Anna B Moseley, Kristen M. O'Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M Stone, Elad Sharon, Cecilia C.S. Yeung, Jerald P. Radich, Harry P. Erba

Blood (2023) 142 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2023-180204

Published: 2023

Journal Articles

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Corentin Orvain, Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Bart L. Scott, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2023-188633

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML.

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Impact of MDS-associated mutations and age on outcomes in NPM1-mutated AML

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Association of CD34+ cell dose on outcome after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (PBSCT) for adults with Acute Myeloid Leukemia (AML) in measurable residual disease (MRD)-negative remission

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)

Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only